Eighty patients with chronic unilateral shoulder pain were randomized to receive ultrasound-guided distal suprascapular nerve block (SSNB) at either the spinoglenoid notch (n=40) or the suprascapular notch (n=40). The primary outcome of interest was the Shoulder Pain and Disability Index (SPADI) score. Secondary outcomes of interest included visual analog scale (VAS) pain scores, range of motion (ROM), pain pressure threshold (PPT), patient satisfaction, and the incidence of adverse events. Outcomes were assessed at baseline and at 1, 4, and 12 weeks post-injection. Overall, the results of the study revealed statistically significant improvements in SPADI, VAS scores, and ROM measurements in both groups with no significant differences in the efficacy and safety between the two approaches. The study suggests that the spinoglenoid notch approach is not inferior to the suprascapular notch approach.